
    
      Patients with SLOS receiving dietary cholesterol supplementation are given simvastatin, a
      drug that decreases the activity/expression of HMG-CoA reductase, an enzyme that controls the
      first step of the cholesterol synthesis pathway, reduces the accumulation of toxic
      7-dehydrocholesterol (immediate metabolic precursor of cholesterol) and improve
      neurocognitive and behavioral outcomes.
    
  